1. GSK aims to make 1B doses of vaccine booster for multiple COVID-19 partners — Protalix and Chiesi get close to potential Fabry disease treatment approval — AstraZeneca locks up COVID-19 vaccine supply with Oxford BioMedica deal — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Client Services

Discussion in 'Genoptix' started by Anonymous, Sep 19, 2013 at 4:17 PM.

  1. Anonymous

    Anonymous Guest

    We need JW back. Bunch of clueless idiots running the show.
     
  2. Anonymous

    Anonymous Guest

    CS??? Wow when I worked there they were the best thing going for the company. Not a good sign. Who's JW? Not sure I knew a JW in CS.....
     
  3. Anonymous

    Anonymous Guest

    Joni Wornkey, the only one that knows logistics.
     
  4. Anonymous

    Anonymous Guest

    What is logistics doing wrong now?
     
  5. Anonymous

    Anonymous Guest

    Man she was a constant complainer!
     
  6. Anonymous

    Anonymous Guest

    She was a pain but involved and in charge.
     
  7. Anonymous

    Anonymous Guest

    We just changed our near perfect courier service of many years.
    Who in a right mind would do that?
     
  8. Anonymous

    Anonymous Guest

    payoff!
     
  9. Anonymous

    Anonymous Guest

    Someone should investigate it BUT nobody cares in here.
     
  10. Anonymous

    Anonymous Guest

    There is something strange about it.We are told to use the new company (SBA) but give them USA courier's agent info.
    Looks like someone wanted them out real bad.
     
  11. Anonymous

    Anonymous Guest

    LH and JF will be the best qualified CS reps for us, they have a good heart even though they know nothing!
     
  12. Anonymous

    Anonymous Guest

    We should subcontract the whole CS department to an outside company.
     
  13. Anonymous

    Anonymous Guest

    Relax, Feb 2014 Quest will take over.
     
  14. Anonymous

    Anonymous Guest

    Since we changed to SBA, I get few complaints per day but since Sales reps that
    opened the accounts are gone nobody hears about it.
     
  15. Anonymous

    Anonymous Guest

    Why Quest will buy Genoptix? Why Novartis will sell Genoptix?
     
  16. Anonymous

    Anonymous Guest

    Genoptix is no longer profitable, also changes in Healthcare
    is a big factor.
    Novartis is operating Genoptix separate from their other
    businesses because its not exactly a perfect match.
    Quest or other labs can cut the overhead and make it
    a great addition to their current business.
     
  17. Anonymous

    Anonymous Guest

    This person knows nothing. Every board has these people that speculate and try to make other employees nervous. They are lame attention seekers. Then they'll come back and respond to this comment with some "bullying" type message. Please don't give any attention to this insecure, loser who has nothing better to do but try and bring other people down. If you're not happy leave and if you decide to stay at a company you hate so much...... You're the loser.
     
  18. Anonymous

    Anonymous Guest

    Will Novartis keep molecular diagnostics and clinical trial division, such as part of facility and people in SAN1 and SAN5, and sell all the others?
     
  19. Anonymous

    Anonymous Guest

    I think Novartis will keep the Clinical trial, since they are very strong in the research area.

    In regard to our angry friend that instead of being thankful and use this warning to look for
    a job, he chooses to mislead his co workers.
    In few months as you are leaving the building with a box under your arm,Just remember that I warned you.
     
  20. Anonymous

    Anonymous Guest

    If Quest Diagnostics were aware of numerous Cartesian medical cover-ups and retaliations involving quality and honesty of patient pathology reports, they would take a second thought. Novartis may be already aware of these issues.